Abstract: The determination of the nucleotide sequence of HIV-1 DNA; identification, isolation and expression of HIV-1 DNA sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HIV-1.

Abstract: Disclosed is the molecular cloning of HTLV-III, the adult leukemia and acquired immune deficiency syndrome (AIDS) virus. Clone BH10 contains a 9.0 Kb viral insert constituting the entire HTLV-III genome. Clones BH8 and BH5 contain viral inserts of 5.5 Kb and 3.5 Kb, respectively. These clones are suitable for the development of diagnostic and therapeutic measures for AIDS, as well as use as probes for the detection of AIDS. By scientific convention, HTLV-III, referred to herein also as HIV, has been renamed as HIV-1.

Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Abstract: Provided herein are hepatitis C virus entry inhibitor oxoacetamide compounds, pharmaceutical compositions thereof, and methods for their use in treatment or prevention of hepatitis C virus infection in a subject in need thereof.

Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Abstract: An inducible siRNA expression polynucleotide and methods for its use are provided. The expression polynucleotide comprises a bicistronic expression cassette that encodes a repressor and a detectable marker, wherein the repressor controls expression of siRNA expression in the absence of an inducer.

Abstract: The present invention relates generally to the synthesis of novel quinolinium salts and derivative compounds. Such salts and compounds are useful for inhibiting the growth of cancer cells.

Abstract: The present invention provides methods for identifying agents useful for inhibiting cancer cells by binding to various nuclear receptor proteins, or to the genes or RNA encoding such proteins.

Abstract: The present invention is directed to methods of identifying agents useful for inhibiting cancer cells. The agents bind to one of the proteins described herein, or to a gene or mRNA encoding such protein. The invention is also directed to methods for inhibiting cancer cells by administering an agent that binds to one of the proteins described herein, or to a gene or mRNA encoding such protein.

Abstract: The present invention provides novel assays for assessing cancerous cell growth. The invention is useful for the identification and validation of oncogenes and tumor suppressors, as well as for the identification and validation of therapeutic compounds for the treatment of cancer.

Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Abstract: Libraries for generating small interfering RNA (siRNA) are provided where the members of the library are optimized to inhibit the expression of genes that encode a predetermined family of proteins. The members of the library target at least mRNA encoding all members of the family of proteins. Methods for generating siRNA libraries of the present invention are also provided.

Abstract: The present invention relates to methods and compositions for the elucidation of gene function and the identification of novel genes. Specifically, the present invention relates to methods and compositions for improved functional genomic screening, functional inactivation of specific essential or non-essential genes, and identification of genes that are modulated in response to specific stimuli or encode recognizable phenotypic traits. In particular, the compositions of the present invention include, but are not limited to, expression cassettes comprising a novel dual promoter transcription system, that utilizes modified promoters, preferably containing complementary termination sequences, positioned across a coding sequence and in opposite orientation to each other. In addition, the present invention includes libraries comprising the expression cassettes of the invention, including vectors for transforming cells, such as replication-deficient retroviral vectors.

Abstract: The present invention relates to methods and compositions for the elucidation of gene function and the identification of novel genes. Specifically, the present invention relates to methods and compositions for improved functional genomic screening, functional inactivation of specific essential or non-essential genes, and identification of genes that are modulated in response to specific stimuli or encode recognizable phenotypic traits. In particular, the compositions of the present invention include, but are not limited to, expression cassettes comprising a novel polymerase primer hairpin linker that allows rapid construction of a single transcriptional unit encoding both strands of a hairpin siRNA, regardless of sequence. In addition, the present invention includes libraries comprising the expression cassettes of the invention, including vectors for transforming cells, such as replication-deficient retroviral vectors.

Abstract: The determination of the nucleotide sequence of HTLV-III DNA; identification, isolation and expression of HTLV-III sequences which encode immunoreactive polypeptides by recombinant,DNA methods and production of viral RNA are disclosed. Such polypeptides can be employed in immunoassays to detect HTLV-III.

Abstract: The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.

Abstract: The invention provides non-primate lentiviral vectors, packaging cells and packaging plasmids based, for example, on feline and ungulate retroviruses. In particular, the packaging plasmids are designed for expression in human cells (which are also used as packaging cells). The vectors of the invention transduce human cells, including difficult to target non-dividing cells of the hematopoietic and nervous system, in vitro and in vivo. The vectors are suitable for general gene transfer to these cells and for gene therapy to treat conditions mediated by these non-dividing cells including cancer and HIV infection.

Abstract: This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including, but not limited to, gene vaccination, gene transfer, gene therapy, and the like. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (minimal Ad vector) and are capable of delivering about 36 kb to about 38 kb of heterologous DNA. The generation and propagation of the minimal Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line.

Abstract: A new human B lymphotropic virus, also designated human herpesvirus-6, has been isolated. DNA, molecular clones, antigenic viral proteins and antibodies having specificity to the new virus have been prepared. Various utilities of the new virus and products derived therefrom have been described.